Multifunctional antibody-conjugated coiled-coil protein nanoparticles for selective cell targeting
Source abstract
Abstract
Nanostructures decorated with antibodies (Abs) are applied in bioimaging and therapeutics. However, most covalent conjugation strategies affect Abs functionality. In this study, we aimed to create protein-based nanoparticles to which intact Abs can be attached through tight, specific, and noncovalent interactions. Initially considered waste products, bacterial inclusion bodies (IBs) have been used in biotechnology and biomedicine. However, the amyloid-like nature of IBs limits their functionality and raises safety concerns. To bypass these obstacles, we have recently developed highly functional α-helix-rich IBs exploiting the natural self-assembly capacity of coiled-coil domains. We used this approach to create spherical, submicrometric, biocompatible and fluorescent protein nanoparticles capable of capturing Abs with high affinity. We showed that these IBs can be exploited for Ab-directed cell targeting. Simultaneous decoration of the nanoparticles with two different Abs in a controllable ratio enabled the construction of a bispecific antibody mimic that redirected T lymphocytes specifically to cancer cells. Overall, we describe an easy and cost-effective strategy to produce multivalent, traceable protein nanostructures with the potential to be used for biomedical applications. STATEMENT OF SIGNIFICANCE: Functional inclusion bodies (IBs) are promising platforms for biomedical and biotechnological applications. These nanoparticles are usually sustained by amyloid-like interactions, which imposes some limitations on their use. In this work, we exploit the natural coiled-coil self-assembly properties to create highly functional, nonamyloid, and fluorescent IBs capable of capturing antibodies. These protein-based nanoparticles are successfully used to specifically and simultaneously target two unrelated cell types and bring them close together, becoming a technology with potential application in bioimaging and immunotherapy.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Bacteriophages and microbial interactions · Monoclonal and Polyclonal Antibodies Research · Advanced Biosensing Techniques and Applications
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (52)
Show source-provided references
1. Characterization of the aggregates formed during recombinant protein expression in bacteria10.1186/1471-2091-6-10 ↗
2. N. Ferrer-Miralles, J. Domingo-Espín, J. Corchero, E. Vázquez, A. Villaverde, Microbial factories for recombinant pharmaceuticals, Microb. Cell Fact.. 8 (2009) 1–8. 10.1186/1475-2859-8-17.10.1186/1475-2859-8-17 ↗
3. Recombinant protein folding and misfolding in Escherichia coli10.1038/nbt1029 ↗
4. Bacterial inclusion bodies: discovering their better half10.1016/j.tibs.2017.01.005 ↗
5. Bacterial inclusion bodies are industrially exploitable amyloids10.1093/femsre/fuy038 ↗
6. Surface cell growth engineering assisted by a novel bacterial nanomaterial10.1002/adma.200900283 ↗
7. Size characterization of inclusion bodies by sedimentation field-flow fractionation10.1016/j.jbiotec.2008.07.1995 ↗
8. Catalytically-active inclusion bodies for biotechnology-General concepts, optimization, and application10.1007/s00253-020-10760-3 ↗
9. Functional protein aggregates: just the tip of the iceberg10.2217/nnm.15.125 ↗
10. Bacterial inclusion bodies: a treasure trove of bioactive proteins10.1016/j.tibtech.2019.12.011 ↗
11. Catalytically active inclusion bodies of L-lysine decarboxylase from E. coli for 1,5-diaminopentane production10.1038/s41598-018-24070-2 ↗
12. Catalytically-active inclusion bodies-carrier-free protein immobilizates for application in biotechnology and biomedicine10.1016/j.jbiotec.2017.04.033 ↗
13. A synthetic reaction cascade implemented by colocalization of two proteins within catalytically active inclusion bodies10.1021/acssynbio.8b00274 ↗
14. Targeting antitumoral proteins to breast cancer by local administration of functional inclusion bodies10.1002/advs.201900849 ↗
15. Engineering secretory amyloids for remote and highly selective destruction of metastatic foci
16. Protein quality in bacterial inclusion bodies10.1016/j.tibtech.2006.02.007 ↗
17. Amyloid-like properties of bacterial inclusion bodies10.1016/j.jmb.2005.02.030 ↗
18. Inclusion bodies: specificity in their aggregation process and amyloid-like structure10.1016/j.bbamcr.2008.06.007 ↗
19. Coiled-coil inspired functional inclusion bodies10.1186/s12934-020-01375-4 ↗
20. Tailoring the properties of (catalytically)-active inclusion bodies10.1186/s12934-019-1081-5 ↗
21. Fusion of a coiled-coil domain facilitates the high-level production of catalytically active enzyme inclusion bodies10.1002/cctc.201501001 ↗
22. Detailed small-scale characterization and scale-up of active YFP inclusion body production with Escherichia coli induced by a tetrameric coiled coil domain
23. Prion domains as a driving force for the assembly of functional nanomaterials10.1080/19336896.2020.1785659 ↗
24. Application of GFP imaging in cancer10.1038/labinvest.2014.154 ↗
25. High-resolution solution NMR structure of the Z domain of staphylococcal protein A10.1006/jmbi.1997.1265 ↗
26. Immobilized protein ZZ, an affinity tool for immunoglobulin isolation and immunological experimentation10.1042/BA20060055 ↗
27. Fc-Binding Ligands of immunoglobulin G: an overview of high affinity proteins and peptides10.3390/ma9120994 ↗
28. Covalent immunoglobulin labeling through a photoactivable synthetic Z domain10.1021/bc200052h ↗
29. 3-2-1: Structural insights from stepwise shrinkage of a three-helix Fc-binding domain to a single helix10.1093/protein/gzx029 ↗
30. Minimizing a binding domain from protein A10.1073/pnas.93.12.5688 ↗
31. A class of costimulatory CD28-bispecific antibodies that enhance the antitumor activity of CD3-bispecific antibodies10.1126/scitranslmed.aaw7888 ↗
32. Blinatumomab versus chemotherapy for advanced acute Lymphoblastic Leukemia10.1056/NEJMoa1609783 ↗
33. Bispecific antibodies in cancer immunotherapy10.1016/j.copbio.2019.11.020 ↗
34. Fc engineering for developing therapeutic bispecific antibodies and novel scaffolds
35. Dual targeting nanoparticle stimulates the immune system to inhibit tumor growth10.1021/acsnano.6b08152 ↗
36. Constructing bifunctional nanoparticles for dual targeting: improved grafting and surface recognition assessment of multiple ligand nanoparticles10.1039/C6NR05478A ↗
37. High-throughput screening methodology to identify alpha-synuclein aggregation inhibitors10.3390/ijms18030478 ↗
38. FTIR-spectroscopy of multistranded coiled coil proteins10.1021/bi983079h ↗
39. Cross-β-sheet supersecondary structure in amyloid folds: techniques for detection and characterization10.1007/978-1-62703-065-6_15 ↗
40. On the binding of congo red to amyloid fibrils10.1002/anie.201916630 ↗
41. Knockdown of HIP1 expression promotes ligand-induced endocytosis of EGFR in HeLa cells
42. Epidermal growth factor receptor (EGFR) signaling in cancer10.1016/j.gene.2005.10.018 ↗
43. Piecing together the family portrait of TCR-CD3 complexes10.1111/imr.12000 ↗
44. Bacterial inclusion bodies: making gold from waste10.1016/j.tibtech.2011.09.003 ↗
45. Bacterial inclusion bodies function as vehicles for dendritic cell-mediated T cell responses10.1038/s41423-019-0298-x ↗
46. Bacterial mimetics of endocrine secretory granules as immobilized in vivo depots for functional protein drugs10.1038/srep35765 ↗
47. Tailor-made catalytically active inclusion bodies for different applications in biocatalysis10.1039/C8CY01891J ↗
48. Bioadhesiveness and efficient mechanotransduction stimuli synergistically provided by bacterial inclusion bodies as scaffolds for tissue engineering10.2217/nnm.11.83 ↗
49. Isolation of biologically active nanomaterial (inclusion bodies) from bacterial cells10.1186/1475-2859-9-66 ↗
50. The biological potential hidden in inclusion bodies10.3390/pharmaceutics12020157 ↗
51. Bispecific antibodies: a mechanistic review of the pipeline10.1038/s41573-019-0028-1 ↗
52. Antibody-conjugated nanoparticles for biomedical applications10.1155/2009/439389 ↗